A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.

Trial Details

NCT ID
NCT07664735
Phase
PHASE1
Sponsor
Outpace Bio, Inc.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • OPB-201
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Minneapolis, Minnesota, United States|44.97997,-93.26384
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Age ≥ 18 years of age at the time of signing the informed consent form.
  • Histologically confirmed diagnosis of endometrial cancer, epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological…
  • Received at least 1 prior line of systemic chemotherapy including a platinum-based chemotherapy.
  • Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →